Childhood visceral leishmaniasis

Indian Journal of Medical Research

Volumn 123, Issue 3, 2006, Pages 353-356

  Bhattacharya, Sujit K ^a,b   Sur, Dipika ^a   Karbwang, Juntra ^c  

^a RAJENDRA MEMORIAL RESEARCH INSTITUTE OF MEDICAL SCIENCES   (India)

^b NATIONAL INSTITUTE OF CHOLERA AND ENTERIC DISEASES   (India)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Childhood VL; Clinical features; Miltefosine; Sodium antimony gluconate

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIMONY GLUCONATE; LEISHMANIA VACCINE; MILTEFOSINE; PAROMOMYCIN; PENTAMIDINE ISETHIONATE; STIBOGLUCONATE SODIUM;

ANOREXIA; AWARENESS; BACTERIAL INFECTION; BLOOD ANALYSIS; BONE MARROW BIOPSY; CARDIOTOXICITY; CHILD; CHILDHOOD DISEASE; CLINICAL FEATURE; CLINICAL PROTOCOL; COMMUNITY CARE; DIABETES MELLITUS; DIAGNOSTIC TEST; DIARRHEA; DISEASE SEVERITY; DISEASE TRANSMISSION; DRUG CHOICE; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; FECES ANALYSIS; FEVER; HEPATOMEGALY; HUMAN; HYPOKALEMIA; INCIDENCE; INDIA; INFECTION CONTROL; INFESTATION; LEISHMANIA DONOVANI; LIVER FUNCTION TEST; MICROSCOPY; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; PARASITE TRANSMISSION; PHLEBOTOMUS; PREVALENCE; REVIEW; RIGOR; SKIN LEISHMANIASIS; SPLENOMEGALY; URINALYSIS; VECTOR CONTROL; VISCERAL LEISHMANIASIS; VOMITING;

ADMINISTRATION, ORAL; AMPHOTERICIN B; ANIMALS; ANTIMONY SODIUM GLUCONATE; ANTIPROTOZOAL AGENTS; HUMANS; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; PHOSPHORYLCHOLINE; PSYCHODIDAE;

EID: 33745216444     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Life in the twenty-first century: a vision for all. World Health Report 1998. Geneva: World Health Organization; 1998 p. 45.
2. Bora D. Epidemiology of visceral leishmaniasis in India. Natl Med J India 1999; 12: 62-8
3. Desjeux P. Human leishmaniasis: Epidemiology and public health aspects. World Health Statist Q 1992; 45: 267-75.
4. Annual Report Rajendra Memorial Research Institute of Medical Sciences; 2002 p. 40.
5. Napier LE. An epidemiological consideration of the transmission of kala-azar in India. Indian Med Res Memoir 1962; 4: 219-65.
6. Singh S, Gilman-Sachs A, Chang KP, Reed SG. Diagnostic and prognostic value of rK39 antigen in Indian leishmaniasis. J Parasitol 1995; 81: 1000-3.
7. Sunder S, Reed SG, Singh VP, Kumar PCK, Murray HW. Rapid accurate field diagnosis of Indian visceral leishmaniasis. Lancet 1998; 351: 563-5.
8. Thakur CP, Narayan S, Ranjan A. Epidemiological, clinical & pharmacological study of antimony-resistant visceral leishmaniasis in Bihar, India. Indian J Med Res 2004; 120: 166-72.
9. Thakur CP, Narayan S. A comparative evaluation of amphotericin B and sodium antimony gluconate, as firstline drugs in the treatment of Indian visceral leishmaniasis. Ann Trop Med Parasitol 2004; 98: 129-38.
10. Thakur CP, Sinha GP, Pandey AK, Kumar N, Kumar P, Hassan SM, et al. Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its continued use as a first-line drug? An observational study of 80 cases. Ann Trop Med Parasitol 1998; 92: 561-9.
11. Thakur CP, Kumar MM, Pandey AK. Comparison of regims of treatment of resistant Kala-azar patients: a randomized study. Am J Trop Med Hyg 1991; 45: 435-40.
12. Thakur CP, Kumar P, Kumar N, Singh GN, Singh AK, Narain S. A randomized comparison of classical mode of administration of amphotericin B with its newer modes of administration in kala-azar. J Assoc Physicians India 1998; 46: 779-83.
13. Thakur CP, Ahmed S. Observations on amphotericin B treatment of kala-azar given in a rural set up in Bihar, India. Indian J Med Res 2001; 113: 14-8.
14. Thakur CP. A single high dose treatment of kala-azar with Ambisome (amphotericin B lipid complex): a pilot study. Int J Antimicrob Agents 2001; 17: 67-70.
15. Jha TK, Sundar S, Thakur CP, Bachmann P, Karbwang J, Fischer C, et al. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl J Med 1999; 341: 1795-800.
16. Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 2002; 347: 1739-46.
17. Bhattacharya SK, Jha TK, Sundar S, Thakur CP, Engel J, Sindermann H, et al. Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India. Clin Infect Dis 2004; 38: 217-21.
18. Sindermann H, Croft SL, Engel KR, Bommer W, Eibl HJ, Unger C, et al. Miltefosine (Impavido): the first oral treatment against leishmaniasis. Med Microbiol Immunol 2004; 193: 173-80.
19. Thakur CP, Kanyok TP, Pandey AK, Sinha GP, Messick C, Olliaro P. Treatment of visceral leishmaniasis with injectable paromomycin (aminosidine). An open-label randomized phase-II clinical study. Trans R Soc Trop Med Hyg 2000; 94: 432-3.
20. Dhiman RC, Sen B. Epidemiology of Kala-azar in rural Bihar (India) using village as a component unit of study. Indian J Med Res 1991; 93: 155-60.
21. Ranjan A, Sur D, Singh VP, Siddique NA, Manna B, Lal CS, et al. Risk factors for Indian kala-azar. Am J Trop Med Hyg 2005; 73: 74-8.